Sign In
Buy FUSN
$13.26
+0 (+0%)
At Close: Sep 04, 2020
Fusion Pharmaceuticals Announces First Quarter 2021 Financial Results and Business Update
07:30am, Tuesday, 11'th May 2021
Phase 1 study of FPI-1434 Phase 1 enrollment continues on track for data in 1H2022 Continuing expansion of pipeline of targeted alpha therapies through recently completed transactions HAMILTON, ON and
Fusion Pharma Shares Move Higher After Trial Collab With Merck For IGF-1R-Expressing Cancer Study
10:46am, Thursday, 06'th May 2021
Fusion Pharmaceuticals Inc (NASDAQ: FUSN) has entered into a clinical trial collaboration with Merck & Co (NYSE: MRK) to evaluate Fusion's lead candidate, FPI-1434, in combination with Merck's
HAMILTON, ON and BOSTON, May 6, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precis
Fusion Pharmaceuticals to Present at the Bloom Burton & Co. Healthcare Investor Conference
08:45am, Wednesday, 14'th Apr 2021
HAMILTON, ON and BOSTON, April 14, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as p
Fusion Pharmaceuticals Announces Preclinical Combination Data Demonstrating Enhanced Efficacy in Multiple Preclinical Tumor Models
08:35am, Saturday, 10'th Apr 2021
Product candidate FPI-1434, when administered with olaparib, resulted in enhanced efficacy against colorectal and lung cancer xenografts Combination of IGF-1R targeted alpha therapy with immune checkp
Fusion Pharmaceuticals Announces Closing of Acquisition of IPN-1087, a Small Molecule Targeting NTSR1, from Ipsen
04:15pm, Thursday, 01'st Apr 2021
HAMILTON, ON and BOSTON, April 1, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as pre
Fusion Pharmaceuticals Announces Fourth Quarter 2020 Financial Results and Business Update
07:30am, Thursday, 25'th Mar 2021
- FPI-1434 Phase 1 study is progressing - Recent transactions and partnerships expand and diversify Fusion's pipeline of targeted alpha therapies in development to treat a broad array of tumor types H
Fusion Pharmaceuticals Initiates Multi-Dose Portion of Phase 1 Trial of FPI-1434 in Patients with Advanced Solid Tumors
08:10am, Thursday, 10'th Dec 2020
Phase 1 Single-Dose Data Show Uptake Across Multiple Tumor Types; No Dose Limiting Toxicities or Treatment-Related Serious Adverse Events HAMILTON, ON and BOSTON, Dec. 10, 2020 /PRNewswire/ -- Fusion
Fusion Pharmaceuticals Announces Second Quarter 2020 Financial Results and Business Update
11:25am, Tuesday, 11'th Aug 2020
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced financial results for t
Fusion Pharmaceuticals to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
12:00pm, Wednesday, 05'th Aug 2020
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that Chief Executive Of
U.S. IPO Week Ahead: Software Provider Jamf Takes The Spotlight In A Diverse 4-IPO Week
09:13am, Saturday, 18'th Jul 2020
Four IPOs and one SPAC plan to raise $663 million in the week ahead, led by Jamf Holding. The IPO market is on a hot streak, and the IPO pipeline is filling up as filing activity remains high.
Stocks To Watch: Vaccine Players, Earnings Blitz And Fiscal Debate
08:24am, Saturday, 18'th Jul 2020
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday
H1 2020 Canadian IPO - CSE leads in number of non-CPC/SPAC IPOs (88%), GFL IPO accounts 77% of IPO amount
01:30pm, Tuesday, 14'th Jul 2020
H1 2020 Canadian IPO - CSE leads in number of non-CPC/SPAC IPOs (88%), GFL IPO accounts 77% of IPO amount
e.l.f. Beauty, Akouos See Activist Actions
09:13pm, Friday, 10'th Jul 2020
Marathon Partners disclosed a large stake in cosmetics retailer e.l.f. Beauty. New Enterprise Associates now has a large stake in the newly public shares of gene-therapies firm Akouos.
U.S. IPO Weekly Recap: Agora Pops 153% While Albertsons Falls Flat In A 6 IPO Week
12:00pm, Saturday, 27'th Jun 2020
Six IPOs raised a combined $1.7 billion this past week. API platform Agora skyrocketed 153% in the best first day pop since 2019 IPO Beyond Meat. Albertsons fin
